Questcor to Report Fourth Quarter and Full Year 2012 Financial Results on
February 26, 2013
ANAHEIM, Calif., Feb. 6, 2013
ANAHEIM, Calif., Feb. 6, 2013 /PRNewswire/ --Questcor Pharmaceuticals, Inc.
(NASDAQ: QCOR) today announced that it will release fourth quarter and full
year 2012 financial results on Tuesday, February 26, 2013 after the close of
the U.S. financial markets. The Company will host a conference call and slide
presentation via webcast on Tuesday, February 26, 2013 at 4:30 p.m. Eastern /
1:30 p.m. Pacific to discuss results and highlights of the quarter and full
year, as well as current corporate developments.
The call can be accessed in the following ways:
oBy webcast: At Questcor's investor relations website,
oBy telephone: For both "listen-only" participants and those participants
who wish to take part in the question-and-answer portion of the call, the
dial-in number in the U.S. is (877) 354-0215. For participants outside the
U.S., the dial-in number is (253) 237-1173.
oBy audio replay: A replay of the conference call will be available for
seven business days following conclusion of the live call. The telephone
dial-in number for U.S. participants is (855) 859-2056. For participants
outside the U.S., the replay dial-in number is (404) 537-3406. The replay
access code for all callers is 95427085.
Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the
treatment of patients with serious, difficult-to-treat autoimmune and
inflammatory disorders. Questcor's primary product is H.P. Acthar^® Gel
(repository corticotropin injection), an injectable drug that is approved by
the FDA for the treatment of 19 indications. Of these 19 indications,
Questcor currently generates substantially all of its net sales from the
following on-label indications: the treatment of acute exacerbations of
multiple sclerosis in adults, the treatment of proteinuria in the nephrotic
syndrome of the idiopathic type, the treatment of infantile spasms in infants
and children under two years of age, and the treatment of certain rheumatology
related conditions, including the treatment of the rare and closely related
neuromuscular disorders dermatomyositis and polymyositis. With respect to
nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a
remission of proteinuria in the nephrotic syndrome without uremia of the
idiopathic type or that due to lupus erythematosus." Questcor is also
exploring the possibility of developing markets for other on-label indications
and the possibility of pursuing FDA approval of additional indications not
currently on the Acthar label where there is high unmet medical need. For
more information about Questcor, please visit www.questcor.com.
SOURCE Questcor Pharmaceuticals, Inc.
Contact: EVC Group, Gregory Gin/Patty Eisenhaur, 646-445-4801/951-316-0577,
Janine McCargo, 646-688-0425, or Doug Sherk, 415-568-4887
Press spacebar to pause and continue. Press esc to stop.